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Metabolomics predicts stroke recurrence
after transient ischemic attack
ABSTRACT
Objective: To discover, by using metabolomics, novel candidate biomarkers for stroke recurrence
(SR) with a higher prediction power than present ones.
Methods: Metabolomic analysis was performed by liquid chromatography coupled to mass spec-
trometry in plasma samples from an initial cohort of 131 TIA patients recruited ,24 hours after
the onset of symptoms. Pattern analysis and metabolomic profiling, performed by multivariate
statistics, disclosed specific SR and large-artery atherosclerosis (LAA) biomarkers. The use of
these methods in an independent cohort (162 subjects) confirmed the results obtained in the first
cohort.
Results:Metabolomics analyses could predict SR using pattern recognition methods. Low concen-
trations of a specific lysophosphatidylcholine (LysoPC[16:0]) were significantly associated with
SR. Moreover, LysoPC(20:4) also arose as a potential SR biomarker, increasing the prediction
power of age, blood pressure, clinical features, duration of symptoms, and diabetes scale
(ABCD2) and LAA. Individuals who present early (,3 months) recurrence have a specific metab-
olomic pattern, differing from non-SR and late SR subjects. Finally, a potential LAA biomarker,
LysoPC(22:6), was also described.
Conclusions: The use of metabolomics in SR biomarker research improves the predictive power of
conventional predictors such as ABCD2 and LAA. Moreover, pattern recognition methods allow us
to discriminate not only SR patients but also early and late SR cases. Neurology® 2015;84:36–45
GLOSSARY
ABCD2 5 age, blood pressure, clinical features, duration of symptoms, and diabetes scale; IDI 5 integrated discrimination
improvement; LAA 5 large-artery atherosclerosis; Lp-PLA 5 lipoprotein-associated phospholipase A; NRI 5 net reclassifi-
cation improvement; LysoPC 5 lysophosphatidylcholine; MS/MS 5 tandem mass spectrometry; PLS-DA 5 partial least
squares discriminant analysis; ROC 5 receiver operating characteristic; SLC 5 solute carrier; SR 5 stroke recurrence.
Stroke is the leading cause of acquired neurologic incapacity.1 In almost 20% of cases, stroke is
preceded by TIA, providing a great opportunity for prevention.2 Thus, the risk of stroke is
particularly high during the few days after the onset of TIA symptoms. However, TIA patients
are a heterogeneous group in terms of symptoms, risk factors, underlying pathology, and early
prognosis.3 The presence of large-artery atherosclerosis (LAA) has been the main established
predictor of subsequent stroke4–6 so far, but a definitive prognostic tool for stroke recurrence
(SR) is not defined.
Recently, in stroke research, there has been significant interest in biomarker development for
predicting SR. Candidate approaches have rendered few biomarkers to be useful in the prognosis
of TIA patients such as C-reactive protein,7 copeptin,8 and lipoprotein-associated phospholipase A
(Lp-PLA),9 but the validity of the proposed biomarkers is debated.10 Regarding biomarker dis-
covery for etiology classification, only the activity of Lp-PLA2 has been shown effective for the
detection of LAA,9,11 and very recently pro–brain natriuretic peptide levels have been associated
with the diagnosis of atrial fibrillation.12
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New techniques such as metabolomics pro-
vide the opportunity to identify new bio-
markers.13 This has been applied in stroke
research14,15 but no description of SR after early
recovery such as that present in TIA patients
appeared.
The aim of the present study was to perform
a metabolomic analysis of plasma from a cohort
of TIA patients in order to find (1) new candi-
date biomarkers associated with SR, (2) tempo-
ral patterns of recurrence, and (3) the potential
impact of LAA in the plasma metabolomic pro-
file. Results were then validated in an indepen-
dent cohort, thus ensuring robustness of the
resulting candidate biomarker.
METHODS Standard protocol approvals, registrations,
and patient consents. The study was approved by the ethics
committee of the Arnau de Vilanova University Hospital. Patient
consent was obtained from all the donors.
Subjects. We prospectively recruited consecutive patients with tran-
sient neurologic deficit who were attended by a neurologist in the
emergency department during the first 24 hours after the onset of
symptoms (REGITELL registry).16 These patients were aleatorized
into 2 cohorts (e-Methods on theNeurology®Web site at Neurology.
org). TIA was defined as acute onset of focal cerebral or monocular
symptoms lasting ,24 hours attributable to brain ischemia. The
number of TIA patients attended in our hospital during the study
period (January 2008 to January 2012) determined the sample size.
Risk factor profile; clinical characteristics; age, blood pressure, clinical
features, duration of symptoms, and diabetes score (ABCD2)17;
ultrasound; and neuroimaging protocols were recorded as described
in e-Methods.
Follow-up and clinical endpoints. Endpoint event was SR. A
stroke physician performed clinical visits during the follow-up at 7
days, 3 months, and every 6 months. Imaging data were required to
confirm brain ischemia in all SR patients considered. Recurrence of
a TIA was not considered an endpoint.
Metabolomic analysis. For nontargeted metabolomics analy-
sis, metabolites were extracted from plasma samples and analyzed
using liquid chromatography coupled to mass spectrometry as
described in e-Methods.
Statistical analysis. Statistics calculations were performed using
SPSS software for Macintosh, version 20 (SPSS, Chicago, IL), R
software, or the Stata 11 statistics package (StataCorp, College Sta-
tion, TX). Further information for tests used appears in e-Methods.
RESULTS Clinical characteristics of the study population.
Table 1 shows baseline characteristics of both cohorts,
comprising 293 patients. As confounders for the me-
tabolomic analyses, we excluded significant differences
in characteristics for vascular risk factors, clinical symp-
toms, ABCD2 score, etiologic subtypes, or discharge
treatments between the 2 cohorts. Previous anticoagu-
lation tended to be more frequent among those pa-
tients from the first cohort. The cohorts did not
differ significantly in terms of SR.
A total of 35 patients had SR. Two patients died
due to recurrent ischemia. In the univariate analysis
(table 2), only LAA and ABCD2 score were associated
with SR. Clopidogrel and anticoagulation at dis-
charge were associated with SR.
Subsequent stroke risk exhibits a specific metabolomic
profile. Untargeted metabolomic analysis in cohort 1
indicated plasma biomarker potentially indicating
future SR. Molecular features detected (present in at
least 50% of samples in the same group) are repre-
sented in the heat map (figure 1B). TIA patients
with SR had a specific metabolomic signature, as
shown by partial least squares discriminant analysis
(PLS-DA) (figure 1C), reaching an accuracy ranging
from 66% (in positive ionization, specificity 5 0.63,
sensitivity 5 0.95) to 73% (in negative ionization,
specificity 5 0.68, sensitivity 5 1). The individual
importance of molecules in the model is presented in
the supplemental data (dataset 1).
Univariate statistics revealed that 94 ions differen-
tiated SR from non-SR patients (p, 0.05) (dataset 2,
supplemental data). By using orthogonal approaches
(exact mass, isotope distribution, tandem mass spec-
trometry [MS/MS], and retention time database), 6
molecules were identified: 1-monopalmitin, dodeca-
noic acid, meso-erythritol, threonate, and lysophos-
phatidylcholine (LysoPC[16:0]) downregulated and
myristoyl-ethanolamine upregulated (p , 0.05) in
SR patients. After pathway analysis, these molecules
clustered into free fatty acid metabolism, energy
metabolism, and solute carrier (SLC)–mediated
transmembrane transport pathways (dataset 3, sup-
plemental data).
Temporal patterns of stroke recurrence define specific
metabolomic profiles. The results (figure 1D) show that
PLS-DA of metabolomic profiles has a high accuracy in
differentiating early SR from later SR groups (dataset 1).
A total of 325 ions differentiated the groups by analysis
of variance (p , 0.05, dataset 2). These molecules (14
metabolites identified among all the differential ions),
indicating early recurrence, clustered into different
metabolic pathways with 13 common between
recurrence and temporal patterns of recurrence,
including fatty acid metabolism (biosynthesis,
transport, and receptors) and regulation of insulin
secretion (table e-1, dataset 3).
Patients with LAA have a specific metabolomic pattern.
We focused on LAA etiology because of its importance
as a SR predictor.4–6 We evaluated metabolomic pro-
files of patients with symptomatic carotid or intracra-
nial stenosis of at least 50%. The results (figure 1E)
revealed that metabolomic profiles are able to offer a
high accuracy predicting presence of LAA (PLS-DA
accuracy 91%–98%, positive: specificity 5 0.79,
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sensitivity 5 1; negative: specificity 5 0.86, sensiti-
vity 5 1; dataset 1). A total of 73 metabolites
were significantly different (Student t test) between
LAA and non-LAA (dataset 2), with the resulting
molecules identified after MS/MS analyses being
androsterone, stearic acid, ascorbic acid, and
LysoPC(22:6), all upregulated in patients with
LAA (p , 0.05).
Table 1 Comparative characteristics, treatments, and stroke recurrence
Variable Cohort 1 (n 5 131) Cohort 2 (n 5 162) Total (n 5 293)
Vascular risk factors
Age, y, mean (SD) 70.5 (11.4) 72.1 (11.2) 71.7 (10.8)
Male 85 (64.9) 94 (58.0) 179 (61.1)
Previous stroke 28 (21.4) 35 (21.6) 63 (21.5)
Hypertension 91 (69.5) 111 (68.5) 201 (68.8)
Coronary disease 18 (13.7) 21 (13.0) 39 (13.3)
Diabetes mellitus 41 (31.3) 47 (29.0) 88 (30.0)
Smoking 18 (13.7) 19 (11.7) 37 (12.6)
Hypercholesterolemia 49 (37.4) 61 (37.7) 110 (37.5)
Previous atrial fibrillation 17 (13.0) 17 (10.5) 34 (11.6)
Basal treatments
Aspirin 30 (22.9) 36 (22.4) 66 (22.6)
Clopidogrel 9 (6.9) 18 (11.2) 27 (9.2)
Anticoagulation 19 (14.5) 12 (7.5) 31 (10.6)
Statins 43 (32.8) 46 (28.6) 89 (30.6)
Renin-angiotensin system blockers 65 (49.6) 78 (48.1) 144 (49.1)
Clinical symptoms
Duration
<10 min 12 (9.3) 17 (10.8) 29 (9.9)
10–59 min 50 (38.2) 61 (37.7) 111 (37.9)
1 h 69 (52.7) 84 (51.9) 153 (52.2)
Cluster TIA 36 (27.5) 33 (20.4) 65 (22.2)
Weakness 70 (53.4) 85 (52.4) 155 (52.9)
Isolated sensory symptoms 12 (9.2) 13 (8.0) 25 (8.5)
Speech impairment 78 (59.5) 103 (64.0) 181 (62.0)
Vertebrobasilar 10 (7.6) 12 (7.5) 22 (7.5)
ABCD2 5.2 (4.0–6.0) 5.1 (4.0–6.0) 5.1 (4.0–6.0)
Etiologic subtypes
Large artery atherosclerosis 33 (25.2) 32 (19.9) 65 (22.3)
Cardioembolism 23 (17.6) 37 (23.0) 60 (20.5)
Small vessel disease 28 (21.4) 30 (18.6) 58 (19.9)
Undetermined cause 47 (35.9) 62 (38.5) 109 (37.3)
DWI (n 5 251) 59 (45.7) 56 (36.8) 115 (40.9)
Time points
Stroke recurrence at 7 days follow-up 6 (4.6) 5 (3.1) 11 (3.8)
Stroke recurrence at 90-day follow-up 8 (6.1) 7 (4.3) 15 (5.1)
Stroke recurrence at 1-year follow-up 13 (9.9) 10 (7.2) 23 (8.5)
Stroke recurrence during the follow-up 20 (15.3) 15 (9.3) 35 (11.9)
Abbreviations: ABCD2 5 age, blood pressure, clinical features, duration of symptoms, and diabetes scale; DWI 5 diffusion-
weighted imaging.
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Results validation using an independent cohort. The
multivariate analysis of an independent cohort
(cohort 2) confirmed (1) metabolomic signature of
SR; (2) metabolomics-based differentiation of SR
temporal patterns; and (3) differences between LAA
and non-LAA (figure e-1, A–C). Common pathways
affected by temporal patterns of recurrence between
the 2 independent cohorts included biosynthesis of
unsaturated fatty acids and SLC-transport-related
pathways (dataset 3). In both cohorts, LysoPC(16:0)
was significantly decreased in early SR patients
(figure 2, A and B), whereas LysoPC(22:6) was
upregulated in LAA patients (figure 2, C and D).
Predictive potential of SR biomarkers described. In order
to define the capacity of these potential biomarkers,
receiver operating characteristic (ROC) curves were
performed using metabolites present in at least
70% of the samples in the same group (SR and
non-SR), pooling both cohorts, due to low
number of SR. The results (figure 2E, table 3, and
table e-2) support the role of plasma LysoPC(20:4)
as a potential biomarker, increasing significantly the
predictive power of ABCD2 or LAA score from
64%–67% to 71%, as assessed by net reclassification
improvement (NRI) or integrated discrimination
improvement (IDI) tests (see supplemental data).
The Hosmer-Lemeshow test for calibration of the
risk of prediction models shows that while the
ABCD2 model was well-calibrated (x2 7.05, p 5
0.069), the ABCD2 1 LAA model was not (x2
13.79, p 5 0.003). The ABCD2 1 LAA 1
LysoPC(20:4) model showed the highest calibration
(x2 3.58, p 5 0.309), whereas the ABCD2 1
LAA 1 LysoPC(16:0) model showed the lowest
calibration values (x2 17.33, p 5 6e-04).
When only early SR was considered, an unidentified
metabolite (figure e-1D) arose as a potential biomarker
also increasing the predictive power of ABCD2 or LAA
score (from 62%–67% to 71%).
DISCUSSION The results demonstrate the feasibility
and utility of the metabolomic approach to reveal
potential biomarkers for SR after TIA, and for its
most frequent independent predictor, LAA. We iden-
tified candidate biomarkers for both SR prediction
and LAA detection, both belonging to LysoPC fam-
ily. These biomarkers arose after analysis in 2 inde-
pendent cohorts (n 5 131; n 5 162), reinforcing
potential study generalizability.
We initially identified that a small set of metabo-
lites are different between SR and no SR. Considering
only this small set of metabolites, we reach an accur-
acy of .60% in segregating these 2 populations,
suggesting that a combination of relatively low num-
ber of metabolites is, at least, as good as previous
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Figure 1 Study design and metabolomics profile of TIA patients
(A) Flow diagram of experiment design. Metabolomic profile of stroke recurrence (SR) and large-artery atherosclerosis (LAA) in TIA patients in cohort 1. (B)
Heat map representation of hierarchical clustering of molecular features found in each sample. Each line of this graphic represents an accurate mass
ordered by retention time, colored by its abundance intensity and baselining to median/mean across the samples. The scale from210 blue (low abundance)
to 110 red (high abundance) represents this normalized abundance in arbitrary units. Tridimensional partial least squares discriminant analysis (PLS-DA)
graphs demonstrate that SR ([C] blue spots represent SR plasma samples; red ones represent non-SR samples) and TIA temporal patterns recurrence ([D]
early recurrence [,90 days] is represented in blue spots, medium [.90 days and,1 any] in red, and late [.1 year] in brown) determine a plasmametabolome.
(E) Tridimensional PLS-DA graphs show differences between patients with LAA. Blue spots represent LAA and red ones non-LAA plasma samples.
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clinical, imaging, or etiologic variables in predicting
SR. Future work devoted to identify these and new
metabolites will help to increase the accuracy of the
test and ultimately develop a more scalable tool for
patients to assess their risk of SR.
Low plasma levels of LysoPC(16:0) arose as a
potential predictor of recurrence, especially in pa-
tients with early SR. This compound is one of the
products of Lp-PLA2 whose levels have been shown
to be increased in adverse prognosis after stroke.11,18
Moreover, high levels of Lp-PLA2 and LysoPC(16:0)
are associated with symptomatic carotid plaques.19
LysoPC(16:0) by itself increases on brain after
stroke20,21 where it mediates phagocyte recruiting22
that can contribute to ischemic brain injury23 and
also produces neuroinflammatory effects when
applied on CNS.24 All these results could pinpoint a
beneficial effect of reduced LysoPC(16:0) levels that
argue against our claim that it marks an early SR risk,
but although high levels of plaque LysoPC(16:0) are
correlated with high plasma and plaque levels of
Lp-PLA2, plasma LysoPC(16:0) levels are not.25 It
Figure 2 Plasma lysophosphatidilcholines as TIA recurrence biomarkers
(A) Lysophosphatidylcholine (LysoPC) (16:0) arose as a potential blood biomarker of stroke recurrence ([A] cohort 1; [B]
cohort 2). **Indicates significant differences (p , 0.0001) by analysis of variance test with Tukey multiple comparison
test. LysoPC(22:6) as a blood biomarker of large-artery atherosclerosis (LAA) ([C] cohort 1; [D] cohort 2). *Indicates signif-
icant differences by Student t test (at least p,0.05). (E) The inclusion of LysoPC (20:4) levels to age, blood pressure, clinical
features, duration of symptoms, and diabetes scale (ABCD2) and LAA score to receiver operating characteristic curve
increase the predictive power of stroke recurrence (areas: ABCD25 0.646, p5 0.0.05; ABCD21 LAA50.678, p50.001;
ABCD2 1 LAA 1 LysoPC(20:4) 5 0.711, p , 0.001; integrated discrimination improvement (IDI) test for comparison of
prediction models: p , 0.0001). (F) Kaplan-Meier estimates of the proportion of patients remaining free from any cerebral
ischemic event. Red line indicates LysoPC(20:4) .1,14,000 MS counts; black line indicates LysoPC(20:4) ,1,14,000 MS
counts. MS 5 mass spectrometry.
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has been demonstrated that plasma LysoPC(16:0) can
inhibit Lp-PLA2 activity both in vitro and in vivo,26
thereby suppressing their neuroinflammative proper-
ties.27 Apart from suppressing Lp-PLA2 activity, plas-
matic LysoPC(16:0) is neuroprotective on brain
ischemia models,28 mainly through activation of
TREK-1 potassium channels.29 Finally, it is known
that LysoPC(16:0) is a potent inducer of superoxide
ion production in endothelial cells30 and controlled
levels of superoxide serve as angiogenic factors in
ischemic angiogenesis.31 Due to all these neuropro-
tective properties, decreased plasma levels of LysoPC
(16:0) could contribute to an early SR risk. Nonethe-
less, when we evaluated potential risk models
accounting LysoPC(16:0), it did not add a significant
value over the clinical parameters explained by
ABCD2 and LAA presence. This fits with the fact
that ABCD2 and LAA are closely related to patho-
physiologic events previously invoked in the homeo-
stasis of LysoPC16:0 (enumerated above).
The potential implication of LysoPC metabolism
in SR was further reinforced by the finding of
LysoPC(20:4) as a potential biomarker of SR based
on ROC curves of aggregated cohorts. Interestingly,
after the use of NRI, IDI, and Hosmer-Lemeshow
test, the statistics indicated that LysoPC(20:4) signif-
icantly improves prediction capacities of combined
ABCD2 and LAA scores. These data are in line
with other LysoPC species containing fatty acids of
20C length, decreased in plasma in experimental
models of ischemia.32 This molecule exhibits anti-
inflammatory potential in preclinical models,33 rein-
forcing the role of inflammation in ischemic recurrence
or tolerance. Interestingly, as with other biomarkers,8,11
LysoPCs exhibit the potential to increase the prognos-
tic accuracy of clinical scores or LAA and could help
management decisions, a hypothesis to be validated in
further studies.
Finally, we identified LysoPC(22:6) as a potential
LAA biomarker. As far as we know, no previous
studies have focused on the role of LysoPC(22:6)
on carotid plaque formation or stability but increased
levels in symptomatic LAA patients could point to a
role in this processes. N-3 polyunsaturated fatty
acids, such as docosahexaenoic acid (22:6), are pre-
cursors of molecules implicated in the resolving phase
of inflammation. Therefore, the higher levels of
LysoPC(22:6) in LAA could be an indicator of reac-
tive response to inflammation associated with ather-
oma plaque development.
As limitations of the present work, we recognize
the significant heterogeneity and small sample size
for SR among the studied population. The metabo-
lome, even in healthy phenotypically similar patients,
exhibits a considerable variance across the time.34–36
Furthermore, the samples were taken in the emergency
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room, without controlling for previous food intake.
Nevertheless, the results provided were strengthened
by the use of 2 independent cohorts. Further, we are
not able to identify an important percentage of metab-
olites present in samples, due to the major bottleneck
in metabolomics: the lack of comprehensive metabolite
databases.37 However, the use of databases repositories
with accurate mass and retention time in reproducible
chromatographic systems will ease the future identifi-
cation of these metabolites.
In the future, metabolomics could be useful to
detect new biomarkers related to other interesting
phenomena related to transient ischemia, the ische-
mic tolerance. Nonlacunar ischemic stroke patients
with recent previous episodes of TIA have a favor-
able outcome, suggesting a neuroprotective effect
of TIA by inducing a phenomenon of precondition
ischemia.38
AUTHOR CONTRIBUTIONS
Mariona Jové: design and conceptualization of the study, analysis and
interpretation of the data, drafting and revising the manuscript for intel-
lectual content. Gerard Mauri-Capdevila: design and conceptualization of
the study, analysis and interpretation of the data, drafting and revising the
manuscript for intellectual content. Idalmis Suárez: analysis of the data,
revising the manuscript for intellectual content. Serafi Cambray: design
and conceptualization of the study, interpretation of the data, revising the
manuscript for intellectual content. Jordi Sanahuja: analysis and interpre-
tation of the data, revising the manuscript for intellectual content.
Alejandro Quílez: analysis and interpretation of the data, revising the
manuscript for intellectual content. Joan Farré: analysis and interpreta-
tion of the data, revising the manuscript for intellectual content. Ikram
Benabdelhak: analysis and interpretation of the data, revising the manu-
script for intellectual content. Reinald Pamplona: design and conceptu-
alization of the study, revising the manuscript for intellectual content.
Manuel Portero-Otín: design and conceptualization of the study, analysis
and interpretation of the data, drafting and revising the manuscript for
intellectual content. Francisco Purroy: design and conceptualization of
the study, analysis and interpretation of the data, drafting and revising the
manuscript for intellectual content.
ACKNOWLEDGMENT
The authors thank the plasma donors for their support and permission.
STUDY FUNDING
Supported by the Autonomous Government of Catalunya (2009SGR-
735), the Spanish Ministry of Health (FIS 11-02033), and the Marató
of TV3 Foundation (95/C/2011). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation
of the manuscript. Samples were obtained with the support of IRBLleida
biobank and RETICS BIOBANCOS (RD09/0076/00059).
DISCLOSURE
The authors report no disclosures relevant to the manuscript. Go to
Neurology.org for full disclosures.
Received February 23, 2014. Accepted in final form August 19, 2014.
REFERENCES
1. Heuschmann PU, Di Carlo A, Bejot Y, et al. Incidence of
stroke in Europe at the beginning of the 21st century.
Stroke 2009;40:1557–1563.
2. Rothwell PM, Warlow CP. Timing of TIAs preceding
stroke: time window for prevention is very short. Neurology
2005;64:817–820.
3. Merwick A, Kelly PJ. Transient ischaemic attack clinics
and management of transient ischaemic attacks. Curr
Opin Neurol 2011;24:50–58.
4. Purroy F, Montaner J, Molina CA, Delgado P, Ribo M,
Alvarez-Sabín J. Patterns and predictors of early risk of
recurrence after transient ischemic attack with respect to
etiologic subtypes. Stroke 2007;38:3225–3229.
5. Ois A, Gomis M, Rodríguez-Campello A, et al. Factors
associated with a high risk of recurrence in patients with
transient ischemic attack or minor stroke. Stroke 2008;39:
1717–1721.
6. Purroy F, Jiménez Caballero PE, Gorospe A, et al. Pre-
diction of early stroke recurrence in transient ischemic
attack patients from the PROMAPA study: a compari-
son of prognostic risk scores. Cerebrovasc Dis 2012;33:
182–189.
7. Purroy F, Montaner J, Molina CA, et al. C-reactive pro-
tein predicts further ischemic events in transient ischemic
attack patients. Acta Neurol Scand 2007;115:60–66.
8. Katan M, Nigro N, Fluri F, et al. Stress hormones predict
cerebrovascular re-events after transient ischemic attacks.
Neurology 2011;76:563–566.
9. Delgado P, Chacón P, Penalba A, et al. Lipoprotein-associated
phospholipase A(2) activity is associated with large-artery ath-
erosclerotic etiology and recurrent stroke in TIA patients.
Cerebrovasc Dis 2012;33:150–158.
10. Whiteley W, Tian Y, Jickling GC. Blood biomarkers in
stroke: research and clinical practice. Int J Stroke 2012;7:
435–439.
11. Cucchiara BL, Messe SR, Sansing L, et al. Lipoprotein-
associated phospholipase A2 and C-reactive protein for
risk-stratification of patients with TIA. Stroke 2009;40:
2332–2336.
12. Purroy F, Suárez-Luis I, Mauri-Capdevila G, et al.
N-terminal pro–brain natriuretic peptide level deter-
mined at different times identifies transient ischaemic
attack patients with atrial fibrillation. Eur J Neurol
2014;21:679–683.
13. Mauri-Capdevila G, Jove M, Suarez-Luis I, Portero-
Otin M, Purroy F. Metabolomics in ischaemic stroke,
new diagnostic and prognostic biomarkers [in Spanish].
Rev Neurol 2013;57:29–36.
14. Jung JY, Lee HS, Kang DG, et al. 1H-NMR-based metab-
olomics study of cerebral infarction. Stroke 2011;42:
1282–1288.
15. Jiang Z, Sun J, Liang Q, et al. A metabonomic approach
applied to predict patients with cerebral infarction. Talanta
2011;84:298–304.
16. Purroy F, Begué R, Gil MI, et al. Patterns of diffusion-
weighted magnetic resonance imaging associated with eti-
ology improve the accuracy of prognosis after transient
ischaemic attack. Eur J Neurol 2011;18:121–128.
17. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al.
Validation and refinement of scores to predict very early
stroke risk after transient ischaemic attack. Lancet 2007;
369:283–292.
18. Tsai TH, Chen YL, Lin HS, et al. Link between
lipoprotein-associated phospholipase A2 gene expression
of peripheral-blood mononuclear cells and prognostic out-
come after acute ischemic stroke. J Atheroscler Thromb
2012;19:523–531.
44 Neurology 84 January 6, 2015
19. Mannheim D, Herrmann J, Versari D, et al. Enhanced
expression of Lp-PLA2 and lysophosphatidylcholine in
symptomatic carotid atherosclerotic plaques. Stroke
2008;39:1448–1455.
20. Shanta SR, Choi CS, Lee JH, et al. Global changes in
phospholipids identified by MALDI MS in rats with focal
cerebral ischemia. J Lipid Res 2012;53:1823–1831.
21. Koizumi S, Yamamoto S, Hayasaka T, et al. Imaging
mass spectrometry revealed the production of lyso-
phosphatidylcholine in the injured ischemic rat brain.
Neuroscience 2010;168:219–225.
22. Zhang Z, Lee YC, Kim SJ, et al. Production of lysophos-
phatidylcholine by cPLA2 in the brain of mice lacking
PPT1 is a signal for phagocyte infiltration. Hum Mol
Genet 2007;16:837–847.
23. Jin R, Yang G, Li G. Inflammatory mechanisms in ische-
mic stroke: role of inflammatory cells. J Leukoc Biol 2010;
87:779–789.
24. Farooqui AA, Horrocks LA. Phospholipase A2-generated
lipid mediators in the brain: the good, the bad, and the
ugly. Neuroscientist 2006;12:245–260.
25. Gonçalves I, Edsfeldt A, Ko NY, et al. Evidence support-
ing a key role of Lp-PLA2-generated lysophosphatidylcho-
line in human atherosclerotic plaque inflammation.
Arterioscler Thromb Vasc Biol 2012;32:1505–1512.
26. Cunningham TJ, Yao L, Lucena A. Product inhibition of
secreted phospholipase A2 may explain lysophosphatidylcho-
lines’ unexpected therapeutic properties. J Inflamm 2008;5:17.
27. Pinto F, Brenner T, Dan P, Krimsky M, Yedgar S. Extra-
cellular phospholipase A2 inhibitors suppress central ner-
vous system inflammation. Glia 2003;44:275–282.
28. Blondeau N, Lauritzen I, Widmann C, Lazdunski M,
Heurteaux C. A potent protective role of lysophospholi-
pids against global cerebral ischemia and glutamate exci-
totoxicity in neuronal cultures. J Cereb Blood Flow Metab
2002;22:821–834.
29. Heurteaux C, Guy N, Laigle C, et al. TREK-1, a K1
channel involved in neuroprotection and general anesthe-
sia. EMBO J 2004;23:2684–2695.
30. Rao SP, Riederer M, Lechleitner M, et al. Acyl chain-
dependent effect of lysophosphatidylcholine on endothelium-
dependent vasorelaxation. PLoS One 2013;8:e65155.
31. Bir SC, Shen X, Kavanagh TJ, Kevil CG, Pattillo CB.
Control of angiogenesis dictated by picomolar superoxide
levels. Free Radic Biol Med 2013;63:135–142.
32. Liu Y, Jia H, Chang X, Ding G, Zhang H, Zou ZM. The
metabolic disturbances of isoproterenol induced myocar-
dial infarction in rats based on a tissue targeted metabo-
nomics. Mol Biosyst 2013;9:2823–2834.
33. Hung ND, Kim MR, Sok DE. Anti-inflammatory action of
arachidonoyl lysophosphatidylcholine or 15-hydroperoxy
derivative in zymosan A-induced peritonitis. Prostaglandins
Other Lipid Mediat 2009;90:105–111.
34. Krug S, Kastenmüller G, Stückler F, et al. The dynamic
range of the human metabolome revealed by challenges.
FASEB J 2012;26:2607–2619.
35. Enea C, Seguin F, Petitpas-Mulliez J, et al. (1)H NMR-
based metabolomics approach for exploring urinary metab-
olome modifications after acute and chronic physical exercise.
Anal Bioanal Chem 2010;396:1167–1176.
36. Park Y, Kim SB, Wang B, et al. Individual variation in
macronutrient regulation measured by proton mag-
netic resonance spectroscopy of human plasma. Am J
Physiol Regul Integr Comp Physiol 2009;297:R202–
R209.
37. Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics:
the apogee of the omics trilogy. Nat Rev Mol Cell Biol
2012;13:263–269.
38. Arboix A, Cabeza N, García-Eroles L, et al. Relevance of
transient ischemic attack to early neurological recovery
after nonlacunar ischemic stroke. Cerebrovasc Dis 2004;
18:304–311.
20 Minutes Pack a Punch
Neurology® Podcasts
• Interviews with top experts on new clinical research in neurology
• Editorial comments on selected articles
• Convenient—listen during your commute, at your desk, or even at the gym
• On demand—it’s there when you want it
• Fun and engaging
• New topic each week
• FREE
Listen now at www.aan.com/podcast
Neurology 84 January 6, 2015 45
